Tixagevimab/cilgavimab in SARS-CoV-2 prophylaxis and therapy: A comprehensive review of clinical experience
K Akinosoglou, EA Rigopoulos, G Kaiafa, S Daios… - Viruses, 2022 - mdpi.com
Effective treatments and vaccines against COVID-19 used in clinical practice have made a
positive impact on controlling the spread of the pandemic, where they are available …
positive impact on controlling the spread of the pandemic, where they are available …
Efficacy and safety of tixagevimab/cilgavimab to prevent COVID-19 (pre-exposure prophylaxis): a systematic review and meta-analysis
S Alhumaid, A Al Mutair, J Alali, N Al Dossary… - Diseases, 2022 - mdpi.com
Background: Tixagevimab/cilgavimab (TGM/CGM) are neutralizing monoclonal antibodies
(mAbs) directed against different epitopes of the receptor-binding domain of the SARS-CoV …
(mAbs) directed against different epitopes of the receptor-binding domain of the SARS-CoV …
Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data
Y Young-Xu, L Epstein, VC Marconi, V Davey… - Mbio, 2023 - Am Soc Microbiol
Little is known regarding the effectiveness of tixagevimab/cilgavimab in preventing SARS-
CoV-2 infection in vaccinated immunocompromised patients, particularly after the …
CoV-2 infection in vaccinated immunocompromised patients, particularly after the …
Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY
Background In the UK, additional COVID-19 vaccine booster doses and treatments are
offered to people who are immunosuppressed to protect against severe COVID-19, but how …
offered to people who are immunosuppressed to protect against severe COVID-19, but how …
Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis prevents breakthrough COVID-19 Infections in immunosuppressed population: 6-Month prospective study
Background: Persons with neuroinflammatory diseases (pwNID) treated with potent
immunosuppressives are at risk of severe COVID-19 outcomes and reduced vaccine …
immunosuppressives are at risk of severe COVID-19 outcomes and reduced vaccine …
Persistent COVID-19 in Immunocompromised Patients–Israeli Society of Infectious Diseases Consensus Statement on Diagnosis and Management
SE Meijer, Y Paran, A Belkin, R Ben-Ami, Y Maor… - Clinical Microbiology …, 2024 - Elsevier
Background Immunocompromised patients with impaired humoral immunity are at risk for
persistent COVID-19 (pCOVID), a protracted symptomatic disease with active viral …
persistent COVID-19 (pCOVID), a protracted symptomatic disease with active viral …
[HTML][HTML] Antiviral therapy of coronavirus disease 2019 (COVID-19)
PY Chen, JT Wang, SC Chang - Journal of the Formosan Medical …, 2024 - Elsevier
The coronavirus disease 2019 (COVID-19) pandemic has reached a turning point. The non-
pharmaceutical interventions for preventing COVID-19 are lifting. Vaccination uptake is …
pharmaceutical interventions for preventing COVID-19 are lifting. Vaccination uptake is …
[HTML][HTML] Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among …
JC Laracy, J Yan, SN Steiger, CA Tan, N Cohen… - …, 2023 - ncbi.nlm.nih.gov
Abstract AZD7442 (tixagevimab-cilgavimab) is a combination of two human monoclonal
antibodies for pre-exposure prophylaxis of severe acute respiratory syndrome coronavirus 2 …
antibodies for pre-exposure prophylaxis of severe acute respiratory syndrome coronavirus 2 …
SARS-CoV-2 infection in high-risk children following tixagevimab–cilgavimab (Evusheld) pre-exposure prophylaxis: a single-center observational study
DR Hijano, JA Ferrolino, EG Swift, CA Michaels… - Frontiers in …, 2023 - frontiersin.org
From 8 December 2021 to 26 January 2023, tixagevimab–cilgavimab (TC) was authorized
for pre-exposure prophylaxis of COVID-19. During this period, we used a multidisciplinary …
for pre-exposure prophylaxis of COVID-19. During this period, we used a multidisciplinary …
The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis
S Glhoom, A Fergany, D El-Araby… - European Journal of …, 2024 - Springer
Background During the COVID-19 pandemic, some populations, including
immunocompromised patients, could not tolerate COVID-19 vaccination or had low …
immunocompromised patients, could not tolerate COVID-19 vaccination or had low …